Troluce Capital Advisors LLC Takes $22.78 Million Position in Ascendis Pharma A/S $ASND

Troluce Capital Advisors LLC bought a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 99,600 shares of the biotechnology company’s stock, valued at approximately $22,782,000. Ascendis Pharma A/S accounts for about 1.4% of Troluce Capital Advisors LLC’s holdings, making the stock its 16th largest holding.

Several other large investors have also recently bought and sold shares of ASND. Perceptive Advisors LLC purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $166,367,000. Wellington Management Group LLP boosted its holdings in shares of Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after purchasing an additional 880,836 shares during the period. Vestal Point Capital LP grew its position in Ascendis Pharma A/S by 200.0% during the third quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock valued at $119,286,000 after purchasing an additional 400,000 shares in the last quarter. Principal Financial Group Inc. increased its stake in Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after buying an additional 232,730 shares during the period. Finally, Fred Alger Management LLC lifted its position in Ascendis Pharma A/S by 106.3% in the 4th quarter. Fred Alger Management LLC now owns 352,109 shares of the biotechnology company’s stock worth $75,084,000 after buying an additional 181,408 shares in the last quarter.

Insider Activity

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jean Jacques Bienaime acquired 400 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the transaction, the director directly owned 400 shares in the company, valued at approximately $95,120. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Price Performance

Shares of ASND stock opened at $253.86 on Monday. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12 month low of $160.86 and a 12 month high of $282.15. The stock has a 50 day moving average of $244.08 and a 200-day moving average of $233.59. The firm has a market cap of $15.84 billion, a PE ratio of 29.28 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. On average, equities analysts predict that Ascendis Pharma A/S will post 4.49 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on ASND shares. Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Barclays upped their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wedbush reissued an “outperform” rating and issued a $273.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Morgan Stanley raised their price objective on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Oppenheimer reissued an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Buy” and an average target price of $296.72.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.